Sign up
XWEL

XWELL Inc. (NASDAQ: XWEL)

Healthcare · Diagnostics & Research

——

Quote unavailable · The latest market session has not been published.

Set alert

The Quantellect read. The borrow fee is 10.83%. Zero active firms cover the stock as of Nov 18, 2026; zero active firms with targets average $7.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationMixed valuation signals

P/S 0.3× vs peer median 4.5×

Momentum—

—

Trend—

—

Short interest—

—

XWEL price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

XWEL · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

5/100Poor

Latest available: Nov 13, 2026 · updates irregularly

Each axis is a 0 to 100 percentile rank among equities

Liquidity6Short48Squeeze19Trend9Momentum12Valuation64Stability19
What each one means
  • Liquidity6

    Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.

  • Short48

    Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.

  • Squeeze19

    Higher scores reflect a higher published Squeeze score within equity peers.

  • Trend9

    Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.

  • Momentum12

    Higher scores reflect stronger 63- and 126-session total returns within equity peers.

  • Valuation64

    Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.

  • Stability19

    Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.

How the Q Score works →

Quantellect signals

Change since Nov 17

Insufficient data · Tide session Nov 17, 2026

Tide40Calm Tide—
Squeeze25Idle—
How the scores work →

How XWEL compares with its industry

Against 44 other US-listed Diagnostics & Research stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Five-year annualized sales growth was 28.4%, higher than 87% of 31 peers.Peer median 7.5% · As of Nov 17, 2026

Points of caution

  1. Trailing-year net margin was -82.9%, with only 7% of 43 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026
  2. Trailing-year return on equity was -361.4%, with only 8% of 40 peers reporting a lower value.Peer median 0.6% · As of Nov 17, 2026
  3. Six-month return was -66.5%, with only 10% of 42 peers reporting a lower value.Peer median 41.9% · As of Nov 16, 2026

Valuation

Mixed valuation signals

  • Price/sales0.26×4.50×
    Lowest 10%

    Higher than 9% of 44 peers

  • Forward P/E10.79×26.77×
    Lowest 10%

    Higher than 10% of 30 peers

  • Price/book20.33×3.38×

    Higher than 84% of 43 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin34.3%55.0%

    Higher than 20% of 41 peers

  • Operating margin−26.1%0.8%

    Higher than 18% of 40 peers

  • Net margin−82.9%0.0%
    Bottom 10% of peers

    Higher than 7% of 43 peers

  • Return on equity−361.4%0.6%
    Bottom 10% of peers

    Higher than 8% of 40 peers

Growth

Growth metrics are mixed versus peers.

  • Quarterly sales growth, year over year−7.1%8.2%

    Higher than 18% of 44 peers

  • 5-year sales growth rate28.4%7.5%

    Higher than 87% of 31 peers

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio2.272.63

    Higher than 46% of 41 peers

  • Debt/equity (total borrowings)—0.45

    Not ranked: only 27 of 44 peers report it

Momentum

Returns are lower than most peers.

  • 1-year return−41.2%+10.8%

    Higher than 19% of 42 peers

  • 6-month return−66.5%+41.9%
    Bottom 10% of peers

    Higher than 10% of 42 peers

  • 3-month return−48.6%+4.7%

    Higher than 19% of 42 peers

Compared with 44 other US-listed Diagnostics & Research stocks · fundamentals as of Nov 15, 2026 · prices as of Nov 16, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

No Coverage

0Strong Buy
0Buy
0Neutral
0Sell
0Strong Sell

Based on 0 active firms as of Nov 18, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$7.00
Average$7.00
High$7.00

As of Nov 18, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q2 2026—−$0.26—
Q1 2026—−$1.51—
Annual 2025—−$5.08—
Q3 2025—−$0.26—
Q2 2025—−$0.56—
Q1 2025—−$1.00—
Annual 2024—−$3.66—
Q3 2024—−$0.99—

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
13FCITADEL ADVISORS LLCClosed position$013F filing
13FCITADEL ADVISORS LLCOpened position$10.3K13F filing
Insider buyWizenberg Gaelle SandraBuy$2.0KForm 4
Insider buyWizenberg Gaelle SandraBuy$368Form 4
Insider buyWizenberg Gaelle SandraBuy$183Form 4
13FCITADEL ADVISORS LLCClosed position$013F filing
13FCITADEL ADVISORS LLCIncreased position$9.9K13F filing
13FCITADEL ADVISORS LLCOpened position$4.2K13F filing
Insider buyWEINSTEIN ROBERTBuy$6.2KForm 4
Insider buyWEINSTEIN ROBERTBuy$6.3KForm 4
All smart-money activity →

News and press releases

All XWEL news →

Company profile

XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers COVID-19 and other medical testing to the traveling public, as well as airline, airport and concessionaire employees, and TSA and

CEO
Mr. Ezra T. Ernst
Headquarters
New York, NY, United States
Employees
175
IPO date
Jan 5, 2018
Sector
Healthcare
Industry
Diagnostics & Research
Website
xwell.com

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.